The 19 analysts offering 1 year price forecasts for MRSA have a max estimate of — and a min estimate of —.
Analyst rating
Based on 24 analysts giving stock ratings to MRSA in the past 3 months.
EPS
0.00
Reported
Estimate
Reported
Estimate
Surprise
Revenue
0.00
Reported
Estimate
Reported
Estimate
Surprise
Be warned
This info isn't a recommendation for what you should personally do, so please don't take the data as investment advice. As with any trade, always look first, then leap. Read more in the Terms of Use.
Frequently Asked Questions
MRSA EPS for the last quarter is 177.71 EUR despite the estimation of 153.93 EUR. In the next quarter EPS is expected to reach 81.24 EUR. Track more of AP MOELLER-MAERSK AS A financials and stay on top of what is up with the company.
According to analysts, MRSA price target is 1,685.22 EUR with a max estimate of 2,315.14 EUR and a min estimate of 1,170.27 EUR. Check if this forecast comes true in a year, meanwhile watch AP MOELLER-MAERSK AS A stock price chart and keep track of the current situation with MRSA news and stock market news.
We've gathered opinions of 24 analysts rating MRSA stock in the past 3 months. Most of them backed up the strong buy trend, and after taking into account other opinions, the overall rating was calculated as neutral. Note that it's not a trading advice — your own analysis is still required.